Evaluation Reports

These drug reviews aim to give objective information and guidance including efficacy, adverse effects, place in treatment and arrangements for prescribing to commissioners of health services, prescribers and others. The drugs are often not yet licensed for the indication. The reports are prepared by a multidisciplinary team within the RDTC and reviewed by health authority personnel and appropriate external specialists.  However, the responsibility for the content and conclusions rests solely with the RDTC.

This information is produced for use by NHS healthcare professionals. See site disclaimer.

NETAG treatment recommendations can be accessed via www.netag.nhs.uk

New documents are restricted to stakeholders only for a period of 3 months following publication:

Document BNF Chapter No.sort descending Published
Sativex for spasticity due to MS (NETAG appraisal) 10.2 Drugs used in neuromuscular disorders - Oct 10
Human Immunodeficiency Virus (HIV) infection - new treatments 5.3 Antiviral drugs - May 10
Tocilizumab for juvenile idiopathic arthritis (NETAG appraisal) (N) 10.1 Drugs used in rheumatic diseases and gout - Jul 10
Panitumumab in the management of metastatic colorectal cancer (N) 8.1 Cytotoxic drugs - Jun 09
Roflumilast for COPD (NETAG appraisal) (N) 3.3 Cromoglycate and related therapy and leukotriene receptor antagonists - Jun 10
Ibritumomab as consolidation therapy after remission induction in previously untreated follicular lymphoma 8.1 Cytotoxic drugs - May 09
Lapatinib in the management of metastatic breast cancer 8.1 Cytotoxic drugs - Nov 08
Azacitidine for the management of myelodysplastic syndromes (N) 8.1 Cytotoxic drugs - May 09
Dasatinib in the management of acute lymphoblastic leukaemia in adults 8.1 Cytotoxic drugs - Aug 08
Aprepitant for the prevention of chemotherapy induced nausea and vomiting 4.6 Drugs used in nausea and vertigo - Mar 09
Perampanel for epilepsy (NETAG appraisal) 4.8 Antiepileptics - Oct 12
Insulin degludec in Diabetes mellitus 6.1 Drugs used in diabetes - Aug 12
Pulmonary arterial hypertension - Current therapeutic strategies 2.5 Hypertension and heart failure - Mar 09
Myocet in the management of metastatic breast cancer 8.1 Cytotoxic drugs - Oct 08
Ruxolitinib for myelofibrosis 8.1 Cytotoxic drugs - Jan 13
Eculizumab in atypical Haemolytic Uraemic Syndrome 9.1 Anaemias and some other blood disorders - Jul 12
Dasatinib in the management of acute lymphoblastic leukaemia in adults 8.1 Cytotoxic drugs - Aug 08
Newer Topical Therapies for Actinic Keratoses 13.8 Sunscreens and camouflagers - Apr 13
Belimumab for the treatment of Systemic Lupus Erythematosus (SLE) 8.1 Cytotoxic drugs - Apr 12
Pasireotide for Cushing’s disease (NETAG Appraisal) 6.5 Hypothalamic and pituitary hormones and anti-oestrogens - Jun 12
Tumour Necrosis Factor Inhibitors for Rheumatoid Arthritis 10.1 Drugs used in rheumatic diseases and gout - May 13
Protease Inhibitors (Boceprevir & Telaprevir) in the treatment of Hepatitis C 5.3 Antiviral drugs - Dec 11
Aflibercept for age-related macular degeneration (NETAG Appraisal) 8.2 Drugs affecting the immune response - Mar 12
Tapentadol for chronic pain 4.7 Analgesics - Jan 15
Sunitinib for the treatment of Pancreatic Neuroendocrine Tumours (PNETs) 8.1 Cytotoxic drugs - Mar 11
Ozurdex dexamethasone ocular implant for uveitis (NETAG appraisal) 8.2 Drugs affecting the immune response - Jan 12
Targinact for chronic pain 4.7 Analgesics - Jan 15
Abiraterone for the treatment of castration-resistant prostate cancer 8.1 Cytotoxic drugs - Feb 11
Botox for chronic migraine (NETAG appraisal) 4.7 Analgesics - Sep 11
Topical gabapentin - Nov 15
Bendamustine for rituximab-refractory non-hodgkin’s lymphoma 8.1 Cytotoxic drugs - Feb 11
Fampridine  for the improvement of walking ability in multiple sclerosis 10.2 Drugs used in neuromuscular disorders - Sep 11
Sufentanil Sublingual Tablet for Post-Operative Pain - Mar 16
Cabazitaxel for the treatment of metastatic hormone-refractory prostate cancer 8.1 Cytotoxic drugs - Feb 11
Rituximab in rheumatoid arthritis: non-NICE approved indications (N) (NETAG APPRAISAL) 10.1 Drugs used in rheumatic diseases and gout - Jul 11
Birch bark extract (Episalvan) for the treatment of partial thickness wounds in adults 13 Skin - Sep 16
Sorafenib for the treatment of locally advanced or metastatic medullary thyroid cancer 8.1 Cytotoxic drugs - Feb 11
Tolvaptan for SIADH (NETAG appraisal) 9.2 Fluids and electrolytes - Apr 11
Vandetanib in locally advanced or metastatic medullary thyroid cancer 8.1 Cytotoxic drugs - Feb 11
Adacolumn in Inflammatory Bowel Disease (NETAG appraisal) 1.5 Chronic bowel disorders - Jan 11
Nanoparticle albumin-bound paclitaxel in the management of metastatic breast cancer 8.1 Cytotoxic drugs - May 10